Besides its activity against the aforementioned TKs and ABC-transporters, pazopanib generates ROS-induced DNA damage in renal cell carcinoma (RCC), as evidenced by increased expression of γH2AX [206]. The gene discussed is ABCG2; the disease is renal cell carcinoma.